| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions. | Disabilità visiva
> Disabilità visiva | Partenariato normativo
> Collaborazione con gli organismi di regolamentazione | Do not know | National | Sometimes | 119063928324 |
| Submissions to the provincial government and advisory briefs to the to INESSS [Institut National d'Excellence en Santé et en Services Sociaux – National Institute of Excellence in Health and Social Services]. | Disabilità visiva
> Degenerazione maculare | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | Regional | Regularly | 115043530962 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Neurologico
> Sclerosi multipla | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 10.000 | National | Regularly | 115059223657 |
| Patient Group Evidence submissions to Canada's Drug Agency (CADTH [Canadian Agency for Drugs and Technologies in Health]), INESSS [Institut national d'excellence en santé et en services sociaux - National Institute of Excellence in Health and Social Services] and BC [British Columbia] Pharmacare. | Respiratorio
> BPCO | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Sometimes | 119013149214 |
| Canadian Drug Agency patient submissions. INESSS [Institut national d'excellence en santé et en services sociaux] (Quebec) patient submissions. | Respiratorio
> Asma e allergia | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Regularly | 119021123567 |
| Canadian Drug Agency patient submissions. | Respiratorio
> Asma e allergia | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Regularly | 119021123567 |
| HTA [Health Technology Assessment] submissions. | Pelle
> Condizioni della pelle: la maggior parte dei tipi | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Regularly | 119022981107 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. We write submissions to the HCA [Health Canada Assessment] process (CDA [Canada's Drug Agency] and INESSS [National Institute for Excellence in Health and Social Services]). | Cancro
> Cancro: sangue | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 10.000 | National | Regularly | 119031899906 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | Gastrointestinale
> Gastrointestinale: la maggior parte dei tipi | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Regularly | 119037340441 |
| We do regular submissions for HTA [Health Technology Assessment]. | Gastrointestinale
> Gastrointestinale: la maggior parte dei tipi | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Regularly | 119037340441 |
| CDA [Canada's Drug Agency] and pCPA [pan-Canadian Pharmaceutical Alliance]. | Cardiovascolare
> Condizioni cardiovascolari e cardiache | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 10.000 | International | Sometimes | 119040619515 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Salute generale
> Salute generale | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 10.000 | National | Sometimes | 119042243488 |
| Through the CDA-AMC [Canadian Drug Agency – Agence des médicaments du Canada]. | Cancro
> Cancro: pelle | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 5000 | National | Regularly | 119042855470 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | Difesa del paziente
> Attivista per la salute | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Difesa del paziente
> Attivista per la salute | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Part of CDA [Canada’s Drug Agency] review process. | Respiratorio
> Malattie polmonari | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 10.000 | Regional | Rarely | 119044465336 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors. | Raro
> Malattie rare: altre | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 1000 | National | Sometimes | 119045262810 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | Cancro
> Cancro: seno | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Regularly | 119049015873 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | Cancro
> Cancro: la maggior parte dei tipi | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 1000 | Regional | Sometimes | 119050786265 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | Pelle
> Alopecia | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 5000 | National | Sometimes | 119050829703 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | Respiratorio
> Fibrosi polmonare | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Regularly | 119050864232 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | Cancro
> Cancro: sangue | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 5000 | National | Regularly | 119050868250 |
| HTA [Health Technology Assessment] submissions for new treatments. | Cancro
> Cancro: vescica | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 10.000 | National | Sometimes | 119051388329 |
| We provide patient input to Canada's Drug Agency when they are deciding whether or not to recommend public reimbursement for new drugs. | Disabilità visiva
> Disabilità visiva | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Regularly | 119061542318 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Cancro
> Cancro: la maggior parte dei tipi | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 1000 | National | Regularly | 119068300611 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | Raro
> Malattia di Pompe | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100 | National | Rarely | 119070062251 |
| We submit HTA [Health Technology Assessment] submissions to Canada Drug Agency. | Respiratorio
> Fibrosi polmonare | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Regularly | 119070095029 |
| CDA [Canadian Drug Agency – Agence des médicaments du Canada], INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Cancro
> Cancro: colorettale | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 10.000 | National | Regularly | 119070177334 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Salute generale
> Obesità | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | International | Regularly | 119071517799 |
| CDA [Canada's Drug Agency] AMC [Agence des médicaments du Canada], INESSS [National Institute of Excellence in Health and Social Services]. | Salute generale
> Obesità | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Regularly | 119072155321 |
| HTA [Health Technology Assessment] assessments and reimbursement reviews. | Educazione del paziente
> Educazione del paziente | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | Do not know | National | Sometimes | 119073221885 |
| We participated in a Canada Drug Agency review of COPD [Chronic Obstructive Pulmonary Disease] medication access recently. | Respiratorio
> Malattie polmonari | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | Do not know | National | Rarely | 119074014255 |
| Patient submissions to CDA [Canada's Drug Agency]. | Reumatico
> Lupus | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | Disabilità visiva
> Disabilità visiva | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | Do not know | National | Regularly | 119076796006 |
| We fully support new technologies and therapies to Health Canada. | Disabilità
> Disabilità: altro | Partenariato normativo
> Contribuire alle presentazioni per l'Autorizzazione all'Immissione in Commercio | 5000 | National | Regularly | 119070019511 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | Persone anziane
> Persone anziane | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 100.000 | National | Regularly | 119020601606 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | Cancro
> Cancro: seno | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 100.000 | National | Regularly | 119049015873 |
| Represent patient issues to regulators. | Raro
> Malattie rare: sangue | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | We do not communicate with patients directly | National | Regularly | 119078414468 |
| Patients participate in Town Halls where some of these issues are addressed. | Sangue
> Malattia falciforme | Partenariato normativo
> Con altri sostenitori della salute | 100 | Regional | Rarely | 119026823537 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Disabilità visiva
> Degenerazione maculare | Influenzare le politiche e la legislazione
> Influenzare le politiche sanitarie e la legislazione | 100.000 | Regional | Regularly | 115043530962 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Persone anziane
> Persone anziane | Influenzare le politiche e la legislazione
> Influenzare le politiche sanitarie e la legislazione | 10.000 | National | Regularly | 119044669631 |
| HTA submissions, other public consultations, awareness-building. | Pelle
> Condizioni della pelle: la maggior parte dei tipi | Influenzare le politiche e la legislazione
> Partecipa alle audizioni pubbliche e alle consultazioni | 100.000 | National | Regularly | 119022981107 |
| Provincial Legislative Advocacy days yearly. | Reumatico
> Sclerodermia | Influenzare le politiche e la legislazione
> Partecipa alle audizioni pubbliche e alle consultazioni | 5000 | National | Regularly | 119071951250 |
| Media representation and direct advocacy to provincial Members of Parliament. | Raro
> Malattie rare: genetiche | Influenzare le politiche e la legislazione
> Mobilitare parlamentari e leader politici | 1000 | Regional | Sometimes | 115035427287 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | Persone anziane
> Persone anziane | Influenzare le politiche e la legislazione
> Mobilitare parlamentari e leader politici | 100.000 | National | Regularly | 119020601606 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Persone anziane
> Persone anziane | Influenzare le politiche e la legislazione
> Mobilitare parlamentari e leader politici | 10.000 | National | Regularly | 119044669631 |
| Getting Besrem [immunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | Cancro
> Cancro: sangue | Influenzare le politiche e la legislazione
> Affrontare barriere/anomalie nell'assistenza medica | 1000 | National | Sometimes | 119022124095 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | Disabilità visiva
> Disabilità visiva | Influenzare le politiche e la legislazione
> Affrontare barriere/anomalie nell'assistenza medica | Do not know | National | Regularly | 119076796006 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | Cancro
> Cancro: sangue | Advocacy per prezzi e accessibilità economica
> Sostenere prezzi equi dei farmaci | 5000 | National | Sometimes | 119020401468 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | Difesa del paziente
> Attivista per la salute | Advocacy per prezzi e accessibilità economica
> Sostenere prezzi equi dei farmaci | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | Neurologico
> Epilessia | Advocacy per prezzi e accessibilità economica
> Sostenere prezzi equi dei farmaci | 5000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | Cancro
> Cancro: la maggior parte dei tipi | Advocacy per prezzi e accessibilità economica
> Sostenere prezzi equi dei farmaci | 1000 | National | Regularly | 119068300611 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective and have written numerous submissions to the authorities about drug access and pricing. | Cancro
> Cancro: sangue | Advocacy per prezzi e accessibilità economica
> Sostenere prezzi equi dei farmaci | 5000 | National | Regularly | 119068939499 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | Raro
> Malattia di Pompe | Advocacy per prezzi e accessibilità economica
> Sostenere prezzi equi dei farmaci | 100 | National | Rarely | 119070062251 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | Cancro
> Cancro: sangue | Advocacy per prezzi e accessibilità economica
> Partecipare alle negoziazioni del comitato di revisione dei prezzi | 5000 | National | Sometimes | 119020401468 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance, alliance of Canada's federal, provincial, and territorial public drug plans that negotiates drug prices on behalf of public payers.]. | Immune
> Immunodeficienze primarie | Advocacy per prezzi e accessibilità economica
> Partecipare alle negoziazioni del comitato di revisione dei prezzi | 5000 | National | Sometimes | 119044550257 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Persone anziane
> Persone anziane | Advocacy per prezzi e accessibilità economica
> Partecipare alle negoziazioni del comitato di revisione dei prezzi | 10.000 | National | Regularly | 119044669631 |
| ... In the past, we have also advocated directly with the pCPA [Provincial Council for Drug Programs], which negotiates drug prices, but this is not a regular occurrence. | Disabilità visiva
> Disabilità visiva | Advocacy per prezzi e accessibilità economica
> Partecipare alle negoziazioni del comitato di revisione dei prezzi | 100.000 | National | Regularly | 119061542318 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. | Cancro
> Cancro: sangue | Advocacy per prezzi e accessibilità economica
> Richiesta di prezzi di vendita ridotti dai produttori | 10.000 | National | Regularly | 119031899906 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | Immune
> Immunodeficienze primarie | Advocacy per prezzi e accessibilità economica
> Monitoraggio e tracciamento dei prezzi dei farmaci/carenze di farmaci | 5000 | National | Sometimes | 119044550257 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | Neurologico
> Epilessia | Advocacy per prezzi e accessibilità economica
> Monitoraggio e tracciamento dei prezzi dei farmaci/carenze di farmaci | 5000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | Cancro
> Cancro: la maggior parte dei tipi | Advocacy per prezzi e accessibilità economica
> Monitoraggio e tracciamento dei prezzi dei farmaci/carenze di farmaci | 1000 | National | Regularly | 119068300611 |
| Patient group submissions—not specific to pricing itself, but to approvals for coverage. | Salute mentale
> Salute mentale: disturbi dell'umore | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | 10.000 | National | Rarely | 119020492804 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | Immune
> Immunodeficienze primarie | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | 5000 | National | Sometimes | 119044550257 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access through Provincial-Territorial formularies. | Neurologico
> Epilessia | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | We do not communicate with patients directly | National | Regularly | 119045277128 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | Respiratorio
> Fibrosi polmonare | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | 100.000 | National | Regularly | 119050864232 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions often. | Disabilità visiva
> Disabilità visiva | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | Do not know | National | Sometimes | 119063928324 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | Raro
> Malattia di Pompe | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | 100 | National | Rarely | 119070062251 |
| HTA submissions, other public consultations, awareness-building. | Pelle
> Condizioni della pelle: la maggior parte dei tipi | Advocacy per prezzi e accessibilità economica
> Partecipare a campagne di sensibilizzazione | 100.000 | National | Regularly | 119022981107 |
| Getting Besrem [mmunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | Cancro
> Cancro: sangue | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 1000 | National | Sometimes | 119022124095 |
| We don't provide information for drug pricing, just advocacy for drug approvals or access. | Reumatico
> Lupus | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 5000 | Regional | No | 119022371395 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | Difesa del paziente
> Attivista per la salute | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors [a form of anti-cancer treatment]. | Raro
> Malattie rare: altre | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 1000 | National | Sometimes | 119045262810 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | Neurologico
> Epilessia | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | We do not communicate with patients directly | National | Regularly | 119045277128 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | Cancro
> Cancro: la maggior parte dei tipi | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 1000 | Regional | Sometimes | 119050786265 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | Cancro
> Cancro: sangue | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 5000 | National | Regularly | 119050868250 |
| We frequently advocate for the approval of new drugs for market access. | Disabilità visiva
> Disabilità visiva | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | Do not know | National | Sometimes | 119063928324 |
| … and have written numerous submissions to the authorities about drug access and pricing. | Cancro
> Cancro: sangue | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 5000 | National | Regularly | 119068939499 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Salute generale
> Obesità | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 100.000 | International | Regularly | 119071517799 |
| Patient submissions to CDA [Canada's Drug Agency]. Ongoing national advocacy for equitable access to care and treatment. | Reumatico
> Lupus | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We often focus on vaccines, but not only those. We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Persone anziane
> Persone anziane | Miglioramento dei percorsi di accesso
> Sostenere un accesso più ampio ai vaccini | 10.000 | National | Regularly | 119044669631 |
| We provide patient input to CDA [Canada Drug Agency] when they are deciding whether or not to recommend public reimbursement for new drugs. We also provide input to provinces. | Disabilità visiva
> Disabilità visiva | Miglioramento dei percorsi di accesso
> Affrontare le disparità nell'accesso e nella gestione | 100.000 | National | Regularly | 119061542318 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, we act as Canada's advocacy group on behalf of sarcoma cancer patients. | Cancro
> Cancro: sarcoma | Miglioramento dei percorsi di accesso
> Miglioramento dell'accesso alle terapie rare/ultra-rare | 5000 | National | Regularly | 119078449674 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | Difesa del paziente
> Attivista per la salute | Contributo del paziente basato sull'evidenza
> Utilizza le informazioni sui pazienti per prendere decisioni informate | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | Pelle
> Alopecia | Contributo del paziente basato sull'evidenza
> Utilizza le informazioni sui pazienti per prendere decisioni informate | 5000 | National | Sometimes | 119050829703 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | Raro
> Malattia di Pompe | Contributo del paziente basato sull'evidenza
> Utilizza le informazioni sui pazienti per prendere decisioni informate | 100 | National | Rarely | 119070062251 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Salute generale
> Obesità | Contributo del paziente basato sull'evidenza
> Utilizza le informazioni sui pazienti per prendere decisioni informate | 100.000 | International | Regularly | 119071517799 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Difesa del paziente
> Attivista per la salute | Contributo del paziente basato sull'evidenza
> Fornire prove del mondo reale (RWE) alle agenzie regolatorie | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| The lived experiences of patients are at the centre of Lupus Canada's work. | Reumatico
> Lupus | Contributo del paziente basato sull'evidenza
> Sfrutta le storie dei pazienti e le narrazioni basate sull'esperienza vissuta | Do not know | National | Regularly | 119041443233 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Salute generale
> Salute generale | Contributo del paziente basato sull'evidenza
> Sfrutta le storie dei pazienti e le narrazioni basate sull'esperienza vissuta | 10.000 | National | Sometimes | 119042243488 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Difesa del paziente
> Attivista per la salute | Contributo del paziente basato sull'evidenza
> Sfrutta le storie dei pazienti e le narrazioni basate sull'esperienza vissuta | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We also submit on behalf of people with lived experience through the Health Technology Assessment opportunities with CAD-AMC [Canada's Drug Agency / l'Agence des médicaments du Canada (CDA-AMC)] and INESSS [Institut national d'excellence en santé et en services sociaux -National Institute of Excellence in Health and Social Services]. | Cancro
> Cancro: la maggior parte dei tipi | Contributo del paziente basato sull'evidenza
> Sfrutta le storie dei pazienti e le narrazioni basate sull'esperienza vissuta | 1000 | National | Regularly | 119068300611 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Cancro
> Cancro: la maggior parte dei tipi | Contributo del paziente basato sull'evidenza
> Sfrutta le storie dei pazienti e le narrazioni basate sull'esperienza vissuta | 1000 | National | Regularly | 119068300611 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Difesa del paziente
> Attivista per la salute | Contributo del paziente basato sull'evidenza
> Condurre sondaggi/ricerche per generare dati | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members regularly participate in CDA [Canadian Drug Agency] surveys and sessions. | Disabilità visiva
> Disabilità visiva | Contributo del paziente basato sull'evidenza
> Condurre sondaggi/ricerche per generare dati | Do not know | National | Sometimes | 119063928324 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV e salute sessuale | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 100 | National | Regularly | 115032094015 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | Gastrointestinale
> Gastrointestinale: la maggior parte dei tipi | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 100.000 | National | Regularly | 119037340441 |
| ... been invited to national roundtables by governments and also by pharma, etc. | Persone anziane
> Persone anziane | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 10.000 | National | Regularly | 119044669631 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective. | Cancro
> Cancro: sangue | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 5000 | National | Regularly | 119068939499 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, We act as Canada's advocacy group on behalf of sarcoma cancer patientsw | Cancro
> Cancro: sarcoma | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 5000 | National | Regularly | 119078449674 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | Neurologico
> Epilessia | Governance istituzionale
> Lavorare efficacemente all'interno di reti multi-stakeholder | We do not communicate with patients directly | National | Regularly | 119045277128 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV e salute sessuale | Tutela dei diritti dei pazienti/miglioramento della qualità della vita
> Proteggere/migliorare l'esperienza del paziente | 100 | National | Regularly | 115032094015 |
| We are a peer-led organization that advocates for one another on patients' rights, on care and treatment. | HIV
> HIV | Tutela dei diritti dei pazienti/miglioramento della qualità della vita
> Proteggere/migliorare l'esperienza del paziente | 1000 | Local | Regularly | 119045557717 |